Developing vaccines is very hard work, as evidenced by Tuesday's news that AstraZeneca is pausing its clinical trials on a COVID-19 vaccine after a patient appeared to develop a serious neurological condition. And that raises an unsettling question: What if a vaccine is further away than most of us expect?

Axios Re:Cap digs in with Stat News reporter Adam Feuerstein, who helped break the AstraZeneca news.